

ECT - Memory Loss

Neurologic Side Effects of Psychiatric Treatments



R. J. Dolan, M.D., M.R.C. Psych

Little is known in psychiatry concerning fundamental disease processes. The relative absence of disease-specific treatments is therefore not surprising. Most physical treatments in psychiatry exert their therapeutic effects in a nonspecific fashion. Lack of disease specificity means that compromises are continually made between beneficial and unwanted treatment effects. Indeed, the goal of most therapeutic developments, given limitations in knowledge concerning disease processes, is to enhance wanted over unwanted effects.

Physical treatments in psychiatry, as in other branches of medicine, aim to ameliorate, arrest, and reverse disease processes. In practice, the arrest or reversal of psychiatric disease is an idealistic and rarely achieved goal. In this, psychiatry shares much in common with neurology in that symptom relief is the principal therapeutic aim.

Despite these limitations, there are many beneficial and effective treatments in psychiatry. The mediation of these effects is generally ascribed to alterations in neuronal function at neuroreceptor sites. However, a lack of pharmacologic and disease specificity means that psychiatric interventions are associated with high rates of unwanted effects. Because of their high prevalence, neurologic side effects are the most important hazards of psychiatric treatments. The recognition of neurologic side effects is therefore of great clinical importance.

This review examines the prevalence, clinical presentation, putative pathophysiology, and management of neurologic side effects of psychiatric treatments. It is not possible within the brief space of this article to cover all treatments in psychiatry; therefore the focus will be on the more conventional and widespread treatments. These include the neuroleptics, lithium, antidepressants, electroconvulsive therapy (ECT), anxiolytics, and psychosurgery.

NEUROLEPTICS

This broad group of compounds constitutes the cornerstone of pharmacologic treatment of the psychoses, particularly schizophrenia. The introduction of potent antipsychotic agents into clinical practice in 1952 was associated with an almost immediate recognition that these agents could result in neurologic side effects.^{1,2} Side effects may for convenience be thought of as acute and chronic, though in reality such a division is arbitrary and artificial. There is little dispute that neuroleptics cause acute neurologic side effects, but there is controversy as to whether they are either necessary or sufficient causes for the emergence of chronic side effects, in particular tardive dyskinesia (TD). This question will be addressed further in considering TD. The most commonly encountered neurologic side effects of neuroleptics are summarized in Table 1.

ACUTE DYSTONIC REACTIONS

Acute dystonic reactions were first reported in association with chlorpromazine treatment. Because of their distribution, they were labeled "facio-bucco-linguo-masticatory dyskinesia" and the similarity with "excito-motor" syndromes seen in the wake of epidemic encephalitis was noted.³ These reactions may be focal or generalized. Their onset, which is abrupt, is associated with com-

Table 1. Neurologic Side Effects of Neuroleptics

Acute dystonic reactions
Akathisia
Parkinsonism
Tardive dyskinesia
Tardive dystonia
Neuroleptic malignant syndrome

Consultant Psychiatrist, National Hospital for Nervous Diseases, Queen Square, London, and Senior Lecturer, Royal Free School of Medicine, Pond Street, London, United Kingdom

Reprint requests: Dr. Dolan, National Hospital for Nervous Diseases, Queen Square, London, WC1N 3BG UK

Copyright © 1990 by Thieme Medical Publishers, Inc., 381 Park Avenue South, New York, NY 10016. All rights reserved

mencement or increments of treatment. The manifestations are varied and extremely distressing to affected patients. The phenomena most frequently encountered are muscle spasms chiefly affecting the head and neck, appearing as involuntary spasm of tongue and mouth muscles, spasm of the masseter preventing mouth opening, facial muscle spasm leading to grimacing, and spasm of the orbicularis oculi resulting in excess blinking or blepharospasm. Ocular involvement, oculogyric crisis, may lead to painful upward gaze lasting minutes or hours. Neck involvement, frequently associated with ocular manifestations, consists of torticollis, antecollis or retrocollis. Involvement of trunk (opisthotonos) or limbs, though less frequent, may lead to bizarre gaits or difficulties in walking.

Acute dystonic effects are usually seen in the first 72 hours of neuroleptic treatment. They affect up to 5% of all patients started on these compounds.⁴ The pathophysiology of acute dystonic reactions is unknown, though the clinical manifestations suggest an excess dopaminergic activity, possibly secondary to acute antagonism of dopamine autoreceptors. Acute dystonic reactions are most prevalent in young male patients.⁵ They can occur with any type of neuroleptic but are seen most often in association with the piperazine side chain phenothiazines and the butyrophenones. They are reversible either spontaneously or with treatment. An episode can usually be terminated abruptly by injection of an antiparkinsonian drug. Treatment with neuroleptics can, however, be continued with only a slight risk of recurrence.

AKATHISIA

This refers to a condition characterized by a subjective sense, frequently accompanied by objective evidence, of restlessness. Although reported in postencephalitic and idiopathic parkinsonism, it is now most frequently encountered in patients on neuroleptic drugs. The condition usually presents in the first month of neuroleptic treatment. A delayed-onset variant, tardive akathisia, is reported in up to 25% of patients with TD.

Patients with akathisia complain of an inability to sit still. Accompanying features include fidgeting, rocking back and forth, crossing and uncrossing the legs, or constant pacing. Motor activity relieves the inner subjective urge to move and, not surprisingly, the condition is frequently mistaken for agitation. The association of an inner urge and an outward motor response bears some resemblance to a tic, though akathisia differs in that the urge to move is constant and the motor component is continuous, stereotyped, and repetitive.

The pathophysiology of drug-induced aka-

thisia is not understood, but may be related to blockade of nonstriatal dopaminergic pathways. Anticholinergic drugs are often ineffective in relieving the condition. Benzodiazepines may help. Often, it is necessary to reduce the dosage of the neuroleptic or substitute another class of compound.

PARKINSONISM

This is the most common neurologic side effect of neuroleptics, occurring in from 20 to 40% of patients treated with such agents.^{1,7} Symptoms, which usually appear in the first 3 weeks of treatment, are both dose-related and drug-related. The piperazine phenothiazines and butyrophenones are the compounds most often implicated in precipitating this syndrome, whereas the substituted benzamides such as sulpiride and thioxanthenes are least often responsible. The condition is seen with increasing frequency with age and in those with underlying cerebral disease.

The clinical manifestations are identical to those of Parkinson's disease, with tremor, rigidity, postural abnormalities, and bradykinesia. Drooling is a frequent accompaniment. Bradykinesia, the earliest manifestation, is usually followed by rigidity, abnormalities of posture, and, lastly, resting tremor. Rigidity and tremor are usually symmetrical. An unusual variant seen following medium to long-term neuroleptic treatment is the occurrence of a 5 to 7 Hz perioral tremor, so-called rabbit syndrome.⁸

The mechanism of drug-induced parkinsonism is blockade of striatal postsynaptic dopamine (D2) receptors, producing a functional deficiency of dopamine at those sites. Treatment of the condition involves either stopping or reducing the neuroleptic or alternatively introducing an anticholinergic agent. However, tolerance to the extrapyramidal effects of neuroleptics develops despite continuation of an offending agent. This phenomenon of tolerance may be related to pharmacokinetic factors, such as increased metabolism.⁹ Withdrawal of the antipsychotic drug usually leads to resolution of parkinsonism within a matter of weeks, though the condition may persist for 6 months or longer.¹⁰ One reason for this appears to be the persistent presence of active metabolites for up to 3 months after discontinuation of treatment.¹¹

TARDIVE DYSKINESIA

TD is a hyperkinetic involuntary movement disorder of diverse and widespread manifestations. The occurrence of the syndrome in association

with
1957
prac
obse
in cl
neur
"tard
was
most
by vi
tence

are c
comr
cal in
TD i
and
gait.
bated
sleep.
quent
floor
ment
protr
tongu
ments
sympt
(bucc
involv
ments
mover
cludes
over
ing wl
tical a
syndre
dyskin
from c
spond.
ens wi
ripher
and we

Al
term r
contro
conditi
solely r
lying d
with th
in this
TD or
whethe
creasec
is very
there i
tions cl
TD, we

be related to
ergic pathways.
ineffective in re-
ines may help.
e dosage of the
class of com-

rologic side ef-
from 20 to 40%
s.^{1,7} Symptoms,
weeks of treat-
g-related. The
utyrophenones
licated in pre-
the substituted
thioxanthines
ndition is seen
e and in those

e identical to
remor, rigidity,
resia. Drooling
dykinesia, the
owed by rigid-
lastly, resting
ally symmetri-
ng medium to
he occurrence
led rabbit syn-

ed parkinson-
otic dopamine
nal deficiency
nt of the con-
reducing the
cing an anti-
e to the extra-
velops despite
This phenom-
pharmacoki-
olism.⁹ With-
ually leads to
a matter of
persist for 6
is appears to
etabolites for
ion of treat-

y movement
anifestations.
n association

with neuroleptic medication was first described in 1957, shortly after the introduction into clinical practice of phenothiazine neuroleptics.¹² Further observations of a hyperkinetic syndrome occurring in close temporal association to commencement of neuroleptic medication followed.¹³⁻¹⁵ The term "orofacial dyskinesia" to describe this syndrome was introduced by Faurbye.¹⁶ TD constitutes the most serious side effect of antipsychotic treatment by virtue of its disfiguring nature and its persistence.

The abnormal movements that comprise TD are coordinated, stereotyped, and rhythmic. Most common is cranial involvement, but limb and truncal involvement are also seen. Functional effects of TD include difficulties in speaking, swallowing, and breathing, and abnormalities of posture or gait. The clinical manifestations may be exacerbated by emotional arousal; they disappear during sleep. The earliest cranial manifestation is frequently a writhing movement of the tongue on the floor of the mouth. More marked facial involvement leads to tongue protrusion, often rapid protrusion and withdrawal (so-called flycatcher tongue), grimacing, lateral chewing jaw movements, and sucking or pursing of the lips. These symptoms may appear singly or in combination (buccolinguomasticatory [BLM] dyskinesia). Limb involvement consists of choreiform or jerky movements that may be accompanied by distal athetoid movements of the limbs. Truncal involvement includes writhing or ballistic movements, rhythmical movements of the body from side to side or rocking when the subject is seated. Multivariate statistical analyses of these movements identify two sub-syndromes of TD, a cephalic and a trunk/limb dyskinesia.¹⁷ Support for such fractionation comes from observations that the cephalic syndrome responds to increased neuroleptic dosage and worsens with anticholinergic treatment while the peripheral types may improve with anticholinergic and worsen with increased neuroleptic.

Although TD is an undoubted effect of long-term neuroleptic treatment, there is considerable controversy as to whether the occurrence of this condition in chronic psychiatric patients is due solely to the effects of neuroleptics, to the underlying disease process, or to an interaction of drugs with the underlying disease state.¹⁸ Central issues in this controversy are whether a condition akin to TD occurred in the preneuroleptic era and whether the prevalence of the condition has increased with increasing use of neuroleptics. There is very little information on the latter point, though there is considerable clinical evidence that conditions characterized by excess movements, akin to TD, were seen in the preneuroleptic era. Kraepelin

described abnormal movements in chronic psychotic patients thus: "Connected with these are, further, smacking and clicking of the tongue. . . . But besides we observe especially in the lip muscles, fine lightning-like or rhythmical twitchings, which in no way bear the stamp of voluntary movements. The same is the case in the tremor of the muscles of the mouth which appears sometimes in speaking. . . ." However, it is uncertain whether these early descriptions are indeed from patients with primary schizophrenic illness or schizophrenic illness secondary to primary neurologic conditions, such as postencephalitic states. Furthermore, TD is described in patients receiving neuroleptics for conditions other than schizophrenia, such as manic-depressive illness.¹⁹

The reported prevalence of TD in populations of patients receiving neuroleptic medication varies from 1 to 40%. Discrepancies in reported prevalence are partly attributable to variations in operational definitions of TD, with some early reports being based solely on the BLM triad. Other variables that may influence prevalence figures include age, duration, type, and dosage of medication. An accepted prevalence figure is 20% of patients on long-term neuroleptic treatment.^{6,20}

Risk factors for the development of the disorder that have emerged from epidemiologic surveys include age, female sex, and underlying cerebral disease or damage.^{20,21} An increased risk of developing the disorder is also reported in patients receiving concurrent anticholinergic drugs.^{22,23} The disorder is most often seen in schizophrenic patients but also occurs in other populations of neuroleptic-treated patients. Indeed, contrary to arguments for special association with schizophrenia, it has been suggested that patients with affective disorder exposed to neuroleptics are at greater risk of developing the disorder.²⁴ The condition is also encountered in postencephalitic states, as a spontaneous condition in up to a quarter of the elderly population,²⁵ during L-dopa therapy, and as minor manifestations in Wilson's disease, Huntington's disease, and Sydenham's chorea. A state-dependent variant has been reported in association with the depressive phase of bipolar affective disorder.²⁶

TD is generally associated with medium to long-term exposure to neuroleptics but can occur with exposure as brief as several weeks. The piperazine side-chain and butyrophenone drugs are associated with an increased risk of developing the disorders while the substituted dibenzamides and newer antipsychotic agents such as clozapine are relatively risk free. The condition may first appear during withdrawal of neuroleptics: withdrawal dyskinesia. There are no consistent findings relat-

ing dosage of neuroleptic to risk of developing the syndrome.

The disorder needs to be distinguished from stereotypies and mannerisms of schizophrenia. The former are repetitive, pointlessly executed, normal movements, while the latter are bizarre, unnatural exaggerations of normal movements.

TD in its full expression may be persistent. However, reversal of the syndrome occurs in a third of patients on withdrawal of the neuroleptic.²⁷ Evidence suggests that such spontaneous remission of TD is inversely correlated with age.²⁸ Specific treatments for TD are lacking. An increase in neuroleptic dosage results in temporary suppression of symptoms. In view of a lack of effective treatments the focus must be on prevention. There is little hard evidence that so-called drug holidays—that is, periods off neuroleptics—lead to a decreased risk of developing the condition. In susceptible individuals it is best to use neuroleptics with a decreased risk of inducing the condition, such as sulpiride or clozapine. In patients who have developed the condition, but in whom there are compelling clinical reasons to continue treatment, a switch to one of the low-risk agents is indicated.

The pathophysiology of the condition is not fully understood. Overstimulation of striatal dopamine systems is the mechanism mainly implicated. The theoretical explanation for dopamine overstimulation in the presence of DA antagonists invokes postsynaptic supersensitivity secondary to blockade of DA receptors.^{29,30} Experimental findings from animal models of TD uphold this hypothesis³¹ although other hypotheses have involved alteration of GABA.

TARDIVE DYSTONIA

Dystonic movements of late onset as a major side effect of neuroleptic medication have been recognized for almost 20 years.³² Tardive dystonia is considered a variant of TD rather than a separate clinical entity. Its clinical manifestations are those of a dystonia with sustained involuntary muscular contractions.³³ Dystonic movements in the form of hyperextension or abduction of limbs, excessive lordosis, and pelvic rotation are frequent accompaniments of TD. In tardive dystonia the dystonic movements are the predominant feature. The condition resembles a primary dystonia and may be focal, segmental or generalized in distribution. A variant is so-called Meige's syndrome, which involves both a lower facial dystonia and blepharospasm, sometimes referred to as the orofacial-mandibular blepharospasm syndrome. As in primary dystonia, it is frequently unrespon-

sive to drugs. The major risk factor is similar to that of TD, namely, prolonged exposure to neuroleptics. However, unlike the latter, it is more frequently encountered in young patients. A relationship between age of onset and bodily distribution of dystonic movements has been noted, with generalized dystonias tending to occur in the young while segmental or focal dystonias occur in older individuals.³³

The onset of the condition has been described after intervals of neuroleptic treatment varying from 3 days to 11 years. Prevalence data are sparse. One study of hospitalized psychiatric patients with chronic illness found a figure of approximately 2%.³⁴ As in TD, it may be masked by increases or remit following decreases or withdrawal of neuroleptics. In a proportion of cases it is persistent after withdrawal of drugs. Treatment is unsatisfactory. Strategies that may be helpful include antidopaminergic drugs, anticholinergics, tetrabenazine, and benzodiazepines.³⁵

NEUROLEPTIC MALIGNANT SYNDROME

This is an uncommon but potentially fatal side effect of neuroleptic medication. Its infrequency and variable clinical features often lead to failure in detection. The full-blown syndrome develops over a matter of 48 to 72 hours. In the majority of cases onset follows primary exposure to neuroleptics, though patients developing neuroleptic malignant syndrome (NMS) may in some instances have had previous exposure to neuroleptics. The syndrome was named in 1968 by Delay³⁶ though fatal reactions in association with neuroleptics were observed shortly after their introduction.^{37,38}

The clinical features include hyperthermia, extrapyramidal symptoms such as parkinsonism, rigidity, dystonia, and tremor, autonomic instability with tachycardia, diaphoresis, lability of blood pressure, tachypneic hypoventilation, alteration of consciousness, stupor, or coma. Dehydration is a feature of most cases on presentation.

Although most authors accept a pathogenic role for neuroleptics, there is a remarkably close resemblance between NMS and fulminating psychotic illnesses recognized before the neuroleptic era. A syndrome of acute catatonic delirium was reported as far back as 1832 by Calmeil and subsequent descriptions outlined potentially fatal psychotic illnesses with features that include hyperthermia, catatonia, and alteration of consciousness frequently ending in coma or death.^{39,40} Varying epithets, including lethal catatonia, catatonic delirious state, délire aigu, exhaustion syndrome, Stauder's lethal catatonia, and hypertoxic schizophrenia have been used to describe this syndrome.

Follow
demor
These
wheth
or suff
A role
rence
are sta
may, E
disord
ously
nowad
More
tics is
disord
Furthe
to rec
lapse
NMS
rogen
L
norma
in 70
92%
liver f
as is p
are ab
be cor
a spec
of thi
necro
of pa
drome
delir-
emia).
includ
mogr
unrec
T
given
is mo
butyr
estim
treat
condi
comm
prime
hypo
role f
seen
dopa
the c
may
better
leads
Symp
trol c

Follow-up studies of these catatonic-delirious states demonstrate an outcome similar to that of NMS.⁴¹ These early observations raise a question as to whether neuroleptics in themselves are necessary or sufficient causes for the development of NMS. A role for neuroleptics is suggested by the occurrence of the syndrome close to the time that they are started or increased in dosage. This association may, however, be spurious in that most psychotic disorders, which might include conditions previously classified as delirious catatonia, are likely nowadays to be treated early with neuroleptics. More compelling evidence for a role for neuroleptics is that NMS is also seen in nonschizophrenic disorders following exposure to neuroleptics.^{42,43} Furthermore, withdrawal of neuroleptics may lead to recovery while reintroduction may lead to relapse of NMS.⁴⁴ There have been suggestions that NMS can be considered a neuroleptic-induced iatrogenic form of lethal catatonia.⁴⁵

Laboratory findings, which may be entirely normal, include a polymorphonuclear leukocytosis in 70% of cases, raised muscle creatinine (CK) in 92%, and myoglobinemia in 70%. Abnormalities of liver function tests are also reported in up to 70%, as is proteinuria in 90% of cases. Raised CK levels are also reported in psychotic patients; this could be construed as evidence that NMS is one facet of a spectrum of disorders for which elevated levels of this enzyme are a marker. Evidence of muscle necrosis on biopsy has been reported in up to half of patients affected. Complications of the syndrome include infection, rhabdomyolysis, renal failure (due to rhabdomyolysis and myoglobinemia), and pulmonary insufficiency. Investigations including electroencephalography, computed tomography, and analysis of cerebrospinal fluid are unremarkable.⁴⁶

The prevalence of NMS is difficult to assess given that the condition is often unrecognized. It is most frequently encountered in association with butyrophenones and piperazine phenothiazines. Estimates of its prevalence among neuroleptic-treated populations vary from 0.5 to 1.5%.⁴⁷ The condition is reported as up to three times more common in males. Little is known concerning the primary pathologic features, though striatal and hypothalamic damage have been postulated.⁴⁸ A role for dopamine is likely in that the condition is seen with agents other than neuroleptics that alter dopamine function.⁴⁹ The overall mortality from the condition is of the order of 20 to 30%. This may well be falling with earlier recognition and better management.⁵⁰ Withdrawal of neuroleptic leads to recovery generally within 7 to 10 days. Symptomatic measures consist of rehydration, control of temperature, and maintenance of cardio-

vascular and renal function. Dopamine agonists are used on the assumption that the syndrome is at least partly due to dopamine blockade. Treatments of this nature with reported beneficial effects include bromocriptine, amantadine, and dantrolene.^{51,52}

LITHIUM

The naturally occurring salt, lithium carbonate, is one of the most effective treatments in psychiatry. Its prime role is in the treatment of cyclic mood disorders, both unipolar and bipolar. Its therapeutic effects are seen with dosages that give a serum level of between 0.5 and 1.2 mEq/liter. Neurologic side effects from lithium are prominent with increasing serum levels above 1.2 mEq/liter. Beyond this range, there develops a coarse tremor, ataxia, dysarthria, drowsiness, hyperreflexia, seizures, myoclonus, coma, and eventually death.⁵³ Occasionally, the signs may be unilateral, suggesting an alternative diagnosis. These side effect are well recognized and careful monitoring of serum lithium levels should prevent their development. Less widely recognized are neurologic reactions occurring within the therapeutic range. The most prevalent of these is a fine hand tremor which may be a transient effect on commencement of lithium or a long-term effect.⁵⁴ Less common are instances of parkinsonism.⁵⁵

The most serious neurologic side effects are rare cases of a neurotoxic reaction in patients on combined lithium and neuroleptic therapy, particularly haloperidol. This is characterized by extrapyramidal and cerebellar signs which may be permanent.⁵⁶⁻⁵⁸ Lithium used concurrently with neuroleptics in bipolar affective patients may also increase the risk of developing TD in this group.¹⁹

ANTIDEPRESSANTS

MONOAMINE REUPTAKE INHIBITORS

This broad class of agents constitutes the mainstay treatment of affective disorders and includes the tricyclics, tetracyclics, and the newer selective monoamine reuptake inhibitors (MARI), such as 5-hydroxytryptophan (5-HT) reuptake inhibitors. Since this grouping contains a wide diversity of pharmacologic compounds, many with a broad spectrum of central effects, the range of side effects is great. However, as a general rule, these compounds are devoid of any permanent neurologic sequelae. This is somewhat surprising given

the structural similarity between the tricyclics and the phenothiazine neuroleptics.

Neurologic side effects at toxic levels or overdosage are largely attributable to anticholinergic effects, which include confusion, distractibility, hallucinations, slurred speech, insomnia, and coma.⁵⁹ At therapeutic levels, like the neuroleptics, the tricyclics and tetracyclics are associated with peripheral antimuscarinic effects, including dry mouth, blurred vision, delayed ejaculation, and urinary retention. Trazodone may cause priapism and permanent impotence.⁶⁰ Central effects are mainly dose related and are seen especially in the elderly. Confusion, reported in 10% of patients, is possibly related to the anticholinergic effects of some MARIs.⁶¹ A fine tremor is seen in approximately 5% of patients on tricyclics, but extrapyramidal effects proper are extremely rare. Alteration of seizure threshold is a potential side effect of all drugs in this class. Isolated cases of NMS are also reported in association with this class of antidepressants.

MONOAMINE OXIDASE INHIBITORS

This chemically broad category of drugs shares a common property of inhibiting oxidative deamination of monoamines. Two subclasses are recognized, with relatively selective potencies for inhibition of monoamine oxidase (MAO) A and B, the two subtypes of MAO enzyme. All compounds in this group are irreversible ("suicide") inhibitors of MAO.

Toxic effects are seen following overdosage and at therapeutic levels. The former consist of agitation, hyperreflexia, hyperpyrexia, hallucinations, and convulsions. At therapeutic levels, neurologic side effects include tremor, insomnia, hallucinations, and confusion. Peripheral neuropathy is seen in a proportion of patients exposed to the hydrazine group of MAO inhibitors.

ANTIANSIETY AGENTS

The main compounds in clinical use for the management of anxiety states are the benzodiazepines. Indeed, they comprise the most widely prescribed psychotropic agents. Newer anti-anxiety compounds, particularly with affinities for central serotonergic receptors, are under evaluation in clinical practice. The principal adverse effects of these agents relate to their potential for causing dependence and abuse. Therefore a physical withdrawal syndrome, of which seizures may be a component, is frequently encountered in patients taking these compounds on a medium to long-

term basis. In patients stabilized on these compounds there are remarkably few side effects. Neurologic side effects are mild and consist of impaired psychomotor performance and impairment of attention on vigilance tasks.^{62,63}

ELECTROCONVULSIVE THERAPY

Since its introduction into psychiatry, this treatment has generated a great deal of controversy with regard to both its efficacy and its side effects. Neurologic side effects are few. They consist principally of memory disturbance. Coarse brain damage as a result of ECT has frequently been claimed but remains unproven.

Transient memory loss, both retrograde and anterograde, is a well recognized and uncontroverted immediate side effect of ECT. A major component of these deficits can be attributed to the effect of severe depression per se on memory functioning. Long-term memory impairment is a frequent subjective complaint of patients who have received ECT. An objective basis to these complaints is established. A disturbance of personal biographic memory is seen in a proportion of patients following ECT.^{64,65} It is less marked with unilateral, nondominant hemisphere (as opposed to bilateral) ECT.

PSYCHOSURGERY

Psychosurgery is now relatively rare in psychiatry. In clinical practice, however, one still encounters patients who have been exposed to this type of intervention. In Great Britain the number of procedures carried out fell from 70 in 1979 to 15 in 1986. It remains a highly controversial intervention in view of the nature of the procedure, its scientific justification, and the ethical issues involved. Many practicing psychiatrists disagree entirely with its use. Those who see a role for psychosurgery limit its usage to patients with severe and intractable anxiety, obsessional disorders, and depressive illness that has not responded to other therapies. Procedures now in use are entirely stereotactic, producing lesions of the inferior frontal white matter (subcaudate tractotomy) and anterior cingulate gyri. The former procedure is performed for affective disorders, anxiety, or depression, while the latter is indicated in intractable obsessional disorders.

There are many problems in evaluating neurologic side effects of psychosurgery particularly as one is dealing with an unusual and atypical population. Furthermore, there is a striking paucity of

indej
and
there
proc
tients
chan
for a
are n
intell

fects
when
of p:
Amo
with
rolep
are g
spons
make
pervi
tib be
psych
with t
7
for th
chiat
in ne
ing a
of ps
precis
mech
thera
prese
now.
there
ments
cesses

1. De
F
e
2. Lat
k
F
3. Del
h
r
4. Ma
d
B
r
2

in these com-
side effects.
consist of im-
d impairment

ERAPY

ychiatry, this
al of contro-
y and its side
w. They con-
ance. Coarse
as frequently

trograde and
id uncontro-
A major com-
ited to the ef-
on memory
airment is a
nts who have
these com-
of personal
ortion of pak-
ked with uni-
; opposed to

rare in psy-
one still en-
posed to this
the number
0 in 1979 to
versial inter-
procedure, its
al issues in-
disagree en-
: for psycho-
i severe and
ers, and de-
ed to other
entirely ste-
rior frontal
and anterior
ure is per-
, or depres-
ractable ob-
uating neu-
rticularly as
ypical popu-
; paucity of

independent studies evaluating the effectiveness and outcome of the procedure. Most data are therefore from centers with a vested interest in the procedure. Epilepsy is reported in up to 3% of patients who have had the procedure. Personality change has been reported in up to 7%.⁶⁶ Curiously, for a procedure that damages cerebral tissue, there are no reports of a fall in intelligence or more focal intellectual deficits.

CONCLUSIONS

The overall frequency of neurologic side effects resulting from psychiatric treatments is low when viewed in the context of the widespread use of psychotropic agents in developed countries. Among psychotropic drugs, the most hazardous, with regard to neurologic side effects, are the neuroleptics. Although side effects from neuroleptics are generally reversible, there are a number of responses that may be irreversible or even fatal. This makes imperative the judicious use and careful supervision of such compounds. However, the potential benefits of neuroleptics in the treatment of the psychoses still far outweigh any risks associated with their use.

The development of more specific treatments for the psychoses is a major endeavour within psychiatry and the pharmaceutical industry. Advances in neuroimaging and molecular genetics are having a major impact on the scientific underpinnings of psychiatry, leading to the acquisition of more precise knowledge concerning pathophysiologic mechanisms. The impact of such knowledge on therapeutic developments is difficult to gauge at present. Therapeutic advances in psychiatry, until now, have largely been due to serendipity, though there is every reason to feel optimistic that treatments based on precise knowledge of disease processes are within our grasp.

REFERENCES

1. Delay J, Deniker P, Harl JM. Utilisation en therapeutique psychiatrique d'une phenothiazine d'action centrale elective. *Ann Med Psychol (Paris)* 1952;110:112-7
2. Labhardt F. Technik, Nebenerscheinungen und Komplikationen der Largactiltherapie. *Schweiz Arch Neurol Psychiatr* 1954;73:338-45
3. Delay J, Deniker P, Ropert H, et al. Syndromes neurologiques experimentaux et therapeutique psychiatrique. *Presse Med* 1959;67:123-6, 201-3
4. Marsden CD, Tarsy D, Baldessarini RJ. Spontaneous and drug induced disorders in psychotic patients. In: *Belson DF, Blumer D, eds. Psychiatric aspects of neurologic disease.* New York: Grune & Stratton 1975: 219-66

5. Ayd F. A survey of drug-induced extrapyramidal reactions. *JAMA* 1961;175:1054-60
6. Marsden CD, Fahn S. Problems in the dyskinesias. In: *Marsden CD, Fahn S, eds. Movement disorders 2.* Butterworth 1987
7. Crane GE. Persistent dyskinesia. *Br J Psychiatry* 1973; 122:395-405
8. Jus K, Jus A, Gautier J, et al. Studies of the actions of certain pharmacological agents on tardive dyskinesia and on the rabbit syndrome. *Int J Clin Pharmacol* 1974;9:138-45
9. Loga S, Curry S, Lader M. Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentration and effects in man. *Br J Clin Pharmacol* 1975;2:197-208
10. Gardos G, Cole J, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. *Am J Psychiatry* 1978; 135:1321
11. Forrest I, Forrest F. Urine color test for the detection of phenothiazine compounds. *Clin Chem* 1960;6:11-15
12. Schonecker M. Ein eigentumliches Syndrom im oralen Bereich bei Megaphen-applikation. *Nervenarzt* 1957; 28:35-42
13. Sigwald J, Bouttierd, Raymondeaud C, Piot C. Quatre cas de dyskinesie facio-linguo-masticatrice à evolution prolongée secondaire à un traitement neuroleptique. *Rev Neurol (Paris)* 1959;100:751-5
14. Hunter R, Earl CJ, Thornicroft S. An apparently irreversible syndrome of abnormal movements following phenothiazine medication. *Proc R Soc Med* 1964;57: 758-62
15. Degkvitz R, Luxenburger O. Das terminale extrapyramidale Insuffizienz bzw. Defektsyndrom infolge chronischer Anwendung von Neuroleptika. *Nervenarzt* 1965;36:173-5
16. Faurbye A, Rasch PJ, Petersen PB, et al. Neurological symptoms in pharmacotherapy of psychosis. *Acta Psychiatr Scand* 1964;40:10-27
17. Kidger T, Barnes T, Trauer T, Taylor EJ. Sub-syndromes of tardive dyskinesia. *Psychol Med* 1980;10:513-20
18. Crow TJ, Owens DGC, Johnston EC, et al. Does tardive dyskinesia exist? *Mod Probl Pharmacopsychiatry* 1983; 21:206-19
19. Dinan TJ, Cohen D. Tardive dyskinesia in bi-polar affective disorder: relationship to lithium therapy. *Br J Psychiatry* 1989;155:55-7
20. Kane J, Smith JM. Tardive dyskinesia: prevalence and risk factors 1959-1979. *Arch Gen Psychiatry* 1982;39: 473-81
21. Smith JM, Oswald WT, Kucharski T, et al. Tardive dyskinesia: age/sex differences in hospitalised schizophrenics. *Psychopharmacology* 1978;58:207-11
22. Fann WE, Lake CR, Gerber CJ, et al. Cholinergic suppression of tardive dyskinesia. *Psychopharmacology* 1974;37:101-7
23. Gerlach J, Reisby N, Randrup A. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. *Psychopharmacology* 1974;34:21-35
24. Kane J, Struve FA, Weinhold P. Strategy for the study of patients at high risk for tardive dyskinesia. *Am J Psychiatry* 1980;137:1265-7
25. Blowers AJ. Epidemiology of tardive dyskinesia in the elderly. *Neuropharmacology* 1981;20:1339-40
26. Cutler NR, Post RM, Rey AC, Bunney WE. Depression-dependent dyskinesias in two cases of manic-depressive illness. *N Engl J Med* 1983;18:1088-9
27. Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia. *Arch Gen Psychiatry* 1982;39:803-16
28. Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. *Arch Gen Psychiatry* 1980;37:1368-73
29. Carlsson A. Biochemical implications of dopa-induced actions on the central nervous system with particular reference to abnormal movements. In: *Barbeau A,*

- McDowell FH, eds. L-Dopa and parkinsonism. Philadelphia: FA Davis, 1970;205-3
30. Klawans HL. The pharmacology of tardive dyskinesias. *Am J Psychiatry* 1973;130:82-6
 31. Clow A, Jenner P, Marsden CD. An experimental model of tardive dyskinesia. *Life Sci* 1978;23:421-4
 32. Keegan DL, Rajput AH. Drug induced dystonia tarda: treatment with L-dopa. *Dis Nerv Sys* 1973;38:167-9
 33. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. *Neurology (NY)* 1982;32:1335-46
 34. Kang UJ, Burk RE, Fahn S. Natural history and treatment of tardive dystonia. *Mov Disord* 1986;36(Suppl 1):121
 35. Freedman JH, Kucharski TL, Wagner RL. Tardive dystonia in a psychiatric hospital. *J Neurol Neurosurg Psychiatry* 1987;50:801-3
 36. Delay J, Deniker P. Drug induced extra-pyramidal syndrome. In: Vinken N, Bruyn G, eds. *Handbook of clinical neurology*. New York: Elsevier 1968;6:248-66
 37. Ayd FJ, Junior JR. Fatal hyperpyrexia during chlorpromazine therapy. *J Clin Psychiatry* 1956;27:189-92
 38. Preston J. Central nervous system reaction to small doses of tranquilizers. *Am Pract Dig Treat* 1959;10:627-30
 39. Aronson MJ, Thompson SB. Complications of acute catatonic excitement. *Am J Psychiatry* 1950;107:216-20
 40. Kellam AM. The neuroleptic malignant syndrome, so called: survey of the world literature. *Br J Psychiatry* 1987;150:752-9
 41. Laskowska D, Urbanik K, Jus A. The relationship between catatonic-delirious state and schizophrenia, in the light of a follow-up study (Stauder's lethal catatonia). *Br J Psychiatry* 1965;111:254-7
 42. Smith JA, Carter JH. Neuroleptic malignant syndrome with a positive Weil-Felix test. *Am J Psychiatry* 1984;141:609
 43. Konikoff F, Kuritzky A, Jerushalmi Y, Theodor E. Neuroleptic malignant syndrome induced by a single injection of haloperidol. *Br Med J* 1984;289:1228-9
 44. Bourgeois M, Tignol J, Henry P. Syndromes malins et morts subites au cours des traitements par neuroleptiques simples et retard. *Ann Med Psychol (Paris)* 1971;2:729-46
 45. Mann S, Caroff SN, Bleier HR, et al. Lethal catatonia. *Am J Psychiatry* 1986;143:1374-81
 46. Caroff S. The neuroleptic malignant syndrome. *J Clin Psychiatry* 1980;41:79-83
 47. Cohen BM, Baldessarini RJ, Pope HG, Lipinski JF. Neuroleptic malignant syndrome. *N Engl J Med* 1985;313:1293
 48. Henderson VW, Wooten GF. Neuroleptic malignant syndrome. A pathogenetic role for dopamine receptor blockade? *Neurology (NY)* 1981;31:132-7
 49. Burke RE, Fahn S, Mayeux R, et al. Neuroleptic malignant syndrome caused by dopamine depleting drugs in a patient with Huntington's chorea. *Neurology (NY)* 1981;31:1022-6
 50. Mueller P, Vester J, Fermaglich J. Neuroleptic malignant syndrome. *JAMA* 1983;249:386-8
 51. Gramato JE, Stern BJ, Ringel A, et al. Neuroleptic malignant syndrome: successful treatment with dantrolene bromocriptine. *Ann Neurol* 1983;14:89-90
 52. Delacour JL, Daoudal P, Chapoutot JL, Roc QB. Traitement du syndrome malin des neuroleptiques par le dantrolene. *Nouv Presse Med* 1981;10:3572-3
 53. Saron BM, Gaird R. Lithium. *Clin Toxicol* 1973;6:257-69
 54. Johns S, Harris B. Tremor. *Br Med J* 1984;288:1309
 55. Tyrer P, et al. Extrapyramidal symptoms in two patients receiving lithium carbonate which worsened following administration of orphenadrine. *Br J Psychiatry* 1981;136-91
 56. Cohen WJ, Cohen NH. Lithium carbonate, haloperidol and irreversible brain damage. *JAMA* 1974;230:1283-7
 57. Thornton WE, Thornton BJP. Lithium intoxication: a report of two cases. *Can Psychiatr Assoc J* 1975;20:281-2
 58. Loudon JB, Waring H. Toxic reactions to lithium and haloperidol. *Lancet* 1976;2:1088
 59. Shopin B, Waters B. The pharmacotherapy of major depressive syndrome. Part 1: Treatment of acute depression. *Psychosomatics* 1980;21:542
 60. Lansky MR, Selzer J. Priapism associated with trazodone therapy: case report. *Clin Psychiatry* 1984;45:232-3
 61. Davies RK, Tucker GJ, Horrow M, Detre TP. Confusional episodes and anti-depressant medication. *Am J Psychiatry* 1971;128:95-99
 62. Betts T, Birtele J. Effects of two hypnotic drugs on actual driving performance next morning. *Br Med J* 1982;285:852
 63. Holstrom C, Lader MH. Benzodiazepine withdrawal phenomena. *Int Pharmacopsychiatry* 1981;16:235-44
 64. Squire LR, Slater PC, Miller PL. Retrograde amnesia and bilateral electroconvulsive therapy. Long-term follow-up. *Arch Gen Psychiatry* 1981;38:89-95
 65. Weiner RD, Rodger HJ, Davidson JRT, Squire LR. Effects of stimulus parameters on cognitive side effects. *Ann NY Acad Sci* 1986;462:315-25
 66. Goktepe EO, Young LB, Bridges PK. A further review of the results of stereotactic subcaudate tractotomy. *Br J Psychiatry* 1975;126:270-80

T
gressiv
tients
the of
gressiv
drug-i
discus
terper
episod
Ir
tom o
logic,
classifi
dated
moder
Ferrie
organ
physio
aspect:
clusior
Neveri
crimin
streets
potent
and ac
ity") ir
be ass
consta
ample
viance
and de
ability
substra
Pe
neurof
and so
small p
lations
or why